← Intuitive Surgical overview

Intuitive Surgical vs Johnson & Johnson: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Intuitive Surgical Inc (ISRG)

Q3 2026
▼3▲1

Intuitive Surgical Beats Q2, But Growth Slows and Competition Heats Up

  • Q2 Earnings Beat and Strong Recurring Revenue Intuitive Surgical beat Q2 2026 expectations with 19% revenue growth to $2.89 billion and 16% worldwide procedure growth. About 85% of sales are recurring, providing steady income. Free cash flow jumped 71% to $1.8 billion, supporting buybacks and new approvals.

    This is the main positive force behind the stock this quarter, showing strong financial performance and cash generation.

  • U.S. Procedure Growth Slowdown U.S. procedure growth slowed to 12% due to ACA subsidy expirations and GLP-1-driven bariatric declines. This deceleration raises concerns about future growth, making the stock sensitive to any further slowdown headlines.

    This is a key negative factor that pressured the stock and highlights a real counterweight to the strong overall results.

  • Class II Recall and Tariff Threats A Class II recall of 454 da Vinci units and tariff threats pressured margins and shares. These issues add costs and uncertainty, weighing on investor sentiment and profitability.

    This is a new negative event that directly impacted margins and stock performance during the quarter.

  • Intensifying Competition from J&J's Ottava Johnson & Johnson's FDA-approved Ottava robot intensifies competition in robotic surgery. This threatens Intuitive Surgical's market share and pricing power, adding pressure on future growth and the stock.

    This is a new competitive development that could erode Intuitive Surgical's dominance and affect long-term growth.

August 2026
▲2▼1

Intuitive Surgical Gains on Procedure Growth, Ion Surge, and New Approvals

  • Strong Procedure and System Growth Worldwide procedures rose 16% and system placements jumped 18% to 468, showing robust demand for da Vinci robots. Recurring revenue now makes up about 85% of sales, providing a steady income base.

    This highlights the core operational momentum that drove the stock.

  • Ion Platform Surge and Cash Flow Growth The Ion platform grew 36%, free cash flow climbed 71% to $1.8 billion, and buybacks plus new approvals like the CE mark for da Vinci SP support growth. Analysts upgraded the stock, and a new Malaysia plant expands Asian capacity.

    These are new positive developments that boosted investor confidence.

  • Rising Competition and U.S. Slowdown Concerns Rising robot competition and concerns about a U.S. slowdown could pressure growth. The stock remains sensitive to any deceleration in headline growth despite its durable recurring-revenue base.

    This is the main risk that could weigh on the stock.

Latest
▲4

Intuitive Surgical: Procedure Growth, New Approvals, and Cash Strength Drive Upside

  • Procedure Growth and System Placements Accelerate Worldwide procedures rose 16% and da Vinci system placements jumped 18% to 468, with U.S. placements up 24%. This shows hospitals are still buying and using Intuitive's robots, which drives recurring revenue and future sales. The stock benefits because growth is durable despite concerns about a U.S. slowdown.

    This is the core demand driver that directly supports revenue and earnings growth, which pushes the stock up.

  • Ion Platform Emerges as Second Growth Engine Ion procedures surged 36% to 48,000, cumulative procedures passed 400,000, and the installed base grew 21% annually. This new lung-cancer diagnosis platform gives Intuitive another source of recurring revenue, reducing reliance on da Vinci and supporting a higher stock valuation.

    It highlights a new, fast-growing revenue stream that diversifies the business and boosts long-term growth prospects.

  • Record Cash Flow Fuels Innovation and Buybacks First-half free cash flow jumped 71% to $1.8 billion, and the company bought back $379 million of stock. Strong cash gives Intuitive flexibility to invest in R&D, expand manufacturing, and return money to shareholders, which supports the stock price by signaling financial health and confidence.

    It shows the company's financial strength and ability to fund growth without sacrificing shareholder returns, a key positive for the stock.

  • Clinical Evidence and New Regulatory Approval Expand Use A landmark meta-analysis showed da Vinci surgery improves outcomes across 13 conditions, and a new CE mark allows transvaginal gynecology with da Vinci SP in Europe. These strengthen the case for adoption, open new markets, and support premium pricing, all of which can lift the stock.

    It provides scientific validation and regulatory expansion that can drive broader adoption and pricing power, directly impacting future revenue.

▲3

ISRG: Solid Procedure Growth and New Products Offset Rising Robot Competition

  • Recurring revenue and procedure growth remain strong Worldwide procedures rose about 16% and system placements jumped 18% to 468, with recurring instrument and service revenue now roughly 85% of sales. That steady, repeat business supports ISRG's price even when headline growth slows.

    Shows the core demand engine still growing, the main support for the stock.

  • Analyst upgrades and software moat reinforce confidence Oppenheimer upgraded ISRG to Outperform with a $500 target, and UBS called the selloff overdone. The company is rolling out 100+ da Vinci 5 software updates and filed for FDA clearances, deepening its technology lead and supporting the stock.

    New analyst actions and product roadmap directly lift investor sentiment and the stock.

  • New Malaysia plant expands supply for Asia growth ISRG will build a 316,000-square-foot manufacturing facility in Penang, Malaysia, starting operations in 2028 and creating 1,200 jobs. This adds capacity for surgical instruments and supports long-term growth in Asia Pacific, a positive for the stock.

    New capacity investment signals confidence and future supply expansion.

July 2026
▼3▲1

Intuitive Surgical Q2 Beat Marred by Recall, Slowdown, and New Rival

  • Q2 Beat and Procedure Growth Intuitive Surgical beat Q2 2026 expectations with revenue up 19% to $2.89 billion, adjusted EPS of $2.80, and 16% worldwide procedure growth. This drove recurring instrument and service revenue, supporting the stock.

    This is the main positive fundamental driver for the period.

  • U.S. Procedure Growth Slowdown U.S. procedure growth slowed to 12% as ACA subsidy expirations left patients uninsured, and GLP-1 drugs reduced bariatric surgeries. This weighed on overall growth and investor sentiment.

    This explains a key negative trend affecting demand.

  • Class II Recall and Tariff Threats A Class II recall of 454 da Vinci units raised regulatory and cost concerns, sending shares down 6.3%. Tariffs also threaten margins, with management warning they could materially alter results.

    These are major negative events that pressured the stock.

  • Competition from J&J's Ottava J&J's FDA-approved Ottava robot now directly challenges da Vinci, threatening market share and pricing power. This competitive threat adds to concerns about future growth.

    This is a new competitive development with negative implications.

▼4

ISRG Plunges on Slowing US Procedures, GLP-1 Headwinds, and New J&J Competition

  • US Procedure Growth Slows on Insurance and GLP-1 US da Vinci procedure growth slowed to 12% from 14% as ACA subsidy expirations left patients uninsured and GLP-1 weight-loss drugs cut bariatric surgeries. This reduces recurring revenue from instruments and services, pressuring ISRG's stock.

    This is the core reason for the stock's decline and the main new negative driver this period.

  • J&J's Ottava Robot Enters US Market Johnson & Johnson received FDA approval for its Ottava surgical robot, directly challenging Intuitive's da Vinci in soft-tissue surgery. This raises competition and could limit ISRG's market share and pricing power, weighing on the stock.

    A new competitive threat that changes the long-term outlook for ISRG's dominance.

  • Full-Year Procedure Growth Guided to Middle of Range Management said full-year procedure growth will likely be near the middle of its 13.5-15.5% range, not the high end. This disappointed investors who expected stronger growth, leading to a sharp sell-off.

    Guidance cut is a key new negative catalyst that drove the stock down.

  • Tariff Headwinds Could Materially Alter Results Intuitive warned that additional tariffs could materially alter its financial results, adding cost pressure. Tariffs raise expenses for imported components, which can squeeze profit margins and reduce earnings.

    Tariff risk is a new explicit warning that adds uncertainty to future profits.

▼3▲1

Intuitive Beats Q2 but Insurance and Tariff Worries Sink Shares

  • Q2 Beat on Procedure Growth and da Vinci 5 Placements Intuitive reported Q2 revenue of $2.89 billion, up 19%, and adjusted EPS of $2.80, both beating expectations. Worldwide procedures grew 16%, with 246 da Vinci 5 systems placed. More procedures and system placements drive recurring instrument and service revenue, directly boosting ISRG's sales and profit.

    This is the core new financial result that shows the company's underlying business is still growing strongly.

  • U.S. Procedure Growth Slows on Insurance Changes U.S. da Vinci procedure growth slowed to 12% as patients lost health insurance after ACA tax credits expired. Management warned this could weigh on demand, and analysts cut price targets. Slower U.S. procedure growth means less recurring revenue from instruments and services, pressuring ISRG's stock.

    This is the main new negative that caused the stock to drop over 9% despite the earnings beat.

  • Class II Recall of da Vinci Components Intuitive issued a voluntary Class II recall of certain da Vinci components due to an E-brake retainer pin issue, affecting 454 units. The recall raises operational and regulatory scrutiny, and the stock fell 6.3% on the news. It adds uncertainty ahead of earnings and could lead to higher costs or reputational damage.

    This is a new negative event that directly hit the stock price and raises questions about product quality and regulatory risk.

  • Tariff-Related Margin Pressure Flagged Intuitive maintained its full-year procedure growth outlook of 13.5-15.5% but flagged tariff-related margin pressure. Tariffs add costs to imported components, which can squeeze profit margins. The company also noted a $28 million tariff refund benefit this quarter, but future tariffs remain a headwind.

    This is a new cost concern that weighs on profitability and was cited as a reason for the stock's decline.

Q2 2026
▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

  • Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.

    This is a new, concrete positive catalyst that directly affects future revenue and earnings.

  • Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.

    This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.

  • AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.

    This is a new angle on how ISRG leverages technology to defend its market leadership.

  • Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.

    This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

June 2026
▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

  • Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.

    This is a new, concrete positive catalyst that directly affects future revenue and earnings.

  • Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.

    This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.

  • AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.

    This is a new angle on how ISRG leverages technology to defend its market leadership.

  • Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.

    This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

  • Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.

    This is a new, concrete positive catalyst that directly affects future revenue and earnings.

  • Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.

    This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.

  • AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.

    This is a new angle on how ISRG leverages technology to defend its market leadership.

  • Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.

    This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

Johnson & Johnson (JNJ)

Q3 2026
▲3

J&J Beats, Raises Guidance, Settles Talc, But Valuation Stretched

  • Q2 Beat, Guidance Raised, Dividend Hiked J&J beat second-quarter estimates, raised full-year revenue guidance to about $101 billion, and increased its dividend for the 64th straight year, signaling steady profit growth and shareholder returns.

    This is the core new financial update that directly boosted investor confidence in the quarter.

  • $5.5B Talc Settlement Removes Major Legal Overhang A $5.5 billion settlement resolved roughly 76,000 talc claims, removing a large legal cloud that had weighed on the stock and reducing uncertainty about future payouts.

    This is a major new event that reduces a key risk factor for the company.

  • Oncology Strength and New Drug Approvals Strong sales from cancer drugs Darzalex, Tremfya, and Erleada, plus new approvals IMAAVY, ICOTYDE, and THERMOCOOL, support future revenue growth and pipeline momentum.

    These new product successes are a key driver of expected future earnings.

  • Growth Prospects vs. Valuation and Competitive Risks A planned ~$20B DePuy Synthes sale and pipeline deals support growth, but MedTech lagged, Firefly Bio dilutes EPS by ~$0.46, Stelara biosimilar competition accelerates, and rivals beat Tecvayli in myeloma. Valuation trades ~40% above GF Value, limiting upside.

    This captures the main counterweights that could cap gains despite positive developments.

August 2026
▲2▼2

J&J's August–October 2026: New Drug Approvals and Pipeline Gains, but Valuation Stretched

  • New Drug Approvals and Pipeline Expansion J&J won approvals for IMAAVY, China's Icotyde, expanded Stelara use, and the THERMOCOOL catheter, while the OTTAVA surgical robot advanced. These new products strengthen future growth prospects.

    This point highlights the key new product approvals that drove positive sentiment during the period.

  • Oncology Sales Growth and Guidance Raise Oncology sales grew 16%, and J&J raised full-year guidance and lifted its dividend for the 64th straight year. This reflects strong business performance and shareholder returns.

    This point captures the financial performance and guidance that supported the stock.

  • Valuation Stretched Above Fair Value JNJ trades roughly 40% above its GF Value estimate, meaning good news is largely priced in. This limits upside and increases risk of a pullback.

    This point provides a key counterweight, showing the stock may be overvalued.

  • Stelara Biosimilar Competition Accelerates Stelara biosimilar competition is accelerating, slowing overall growth despite new drugs cushioning the impact. Icotyde may also cannibalize Tremfya sales.

    This point highlights a significant headwind that could pressure future revenue.

Latest
▲3

J&J pipeline wins and analyst upgrades offset Stelara biosimilar drag

  • New drug data strengthen growth pipeline J&J reported positive new data for IMAAVY in myasthenia gravis, TECVAYLI/CARVYKTI/TREMFYA in myeloma and arthritis, and two-year ICOTYDE results in psoriasis. These support expanded use and future sales, helping replace revenue lost from older drugs.

    Shows the main new scientific catalysts that can lift future revenue and investor confidence.

  • FDA approves dual-energy heart catheter The FDA approved J&J's THERMOCOOL SMARTTOUCH SF dual-energy catheter, which lets doctors use two energy types in one device. This expands J&J's heart-device lineup and could win share in a growing market, supporting MedTech sales.

    A concrete new product approval that adds a near-term revenue driver in MedTech.

  • Analyst upgrades on defensive appeal and new drugs BofA raised its J&J target to $278, citing a re-rating of defensive stocks and higher ICOTYDE forecasts. Another analyst sees a possible all-time high by year-end. Higher targets can pull more buyers into the stock.

    Captures the main new sell-side actions that influence near-term investor sentiment and demand for the shares.

  • Oncology strength vs. Stelara biosimilar pressure J&J expects strong oncology growth from Darzalex, Carvykti and others, but Stelara's patent expiry is cutting sales faster this quarter, with rivals launching copies. The net effect is slower overall growth, though new drugs are cushioning the blow.

    The key counterweight: it explains why growth is not even faster and keeps the stock from rising more.

September 2026
▲3▼1

J&J advances pipeline and growth plans, but faces competitive setbacks

  • Pipeline and growth outlook strengthened J&J struck a CAR-T deal with Sail Biomedicines, reported positive lung-cancer and depression trial results, and reaffirmed double-digit growth guidance by 2030. These moves bolster future revenue prospects.

    This point highlights new pipeline and guidance developments that could drive future growth.

  • New drug approvals and trial success The FDA approved ICOTYDE for psoriasis, offering a new revenue stream as Stelara loses patent protection. Caplyta met its goal in a bipolar I mania trial, potentially adding up to $5 billion in peak sales.

    These approvals and trial results represent new revenue opportunities for J&J.

  • DePuy Synthes sale to raise cash J&J is nearing a ~$20 billion sale of DePuy Synthes to Apollo, which would raise cash for faster-growing areas. This strategic move could fund future growth initiatives.

    The potential sale is a new strategic action that could impact J&J's capital allocation.

  • Competitive and trial setbacks AbbVie's etentamig beat J&J's Tecvayli in myeloma, rivals are advancing in ulcerative colitis, and a licensed depression drug failed its Phase 2 trial. These setbacks pose risks to J&J's market position.

    These competitive and clinical failures could negatively impact J&J's growth and stock price.

▲3▼1

J&J advances pipeline, nears $20B orthopedics sale

  • FDA approves ICOTYDE for psoriasis The FDA approved ICOTYDE, a once-daily pill for moderate-to-severe plaque psoriasis. This new immunology drug can help replace sales lost from Stelara's patent expiry, adding a fresh revenue stream and supporting J&J's long-term growth.

    New US approval expands J&J's immunology franchise and offsets Stelara loss.

  • Caplyta succeeds in bipolar I mania trial J&J's Caplyta hit its main goal in a late-stage trial for bipolar I mania, with symptom relief seen by day three. If approved, this could add up to $5 billion in peak sales, strengthening J&J's neuroscience business.

    Positive Phase 3 data supports label expansion and potential $5B peak sales.

  • Apollo in talks to buy DePuy Synthes for ~$20B Apollo Global is in talks to buy J&J's orthopedics unit, DePuy Synthes, for close to $20 billion. A sale would give J&J cash to invest in faster-growing areas like oncology and immunology, simplifying the company.

    Potential $20B sale accelerates pivot to higher-growth areas and simplifies J&J.

  • Depression drug fails Phase 2 trial A depression drug J&J licensed, JNJ-5120/PIPE-307, missed its primary goal in a mid-stage trial. This is a setback for J&J's pipeline, though the company is still analyzing the full data before deciding next steps.

    Pipeline setback creates a negative counterweight to the positive pipeline news.

▲1▼1

J&J advances pipeline and weighs $20B orthopedics sale

  • Pipeline and growth outlook strengthen J&J struck a CAR-T deal with Sail Biomedicines, reported strong lung-cancer and depression trial results, and reaffirmed guidance with double-digit growth expected by 2030. These add future sales and support the stock.

    Shows the main positive force behind JNJ's price this period.

  • Possible $20B sale of DePuy Synthes J&J is in talks to sell its orthopedics unit for about $20 billion, but could spin it off or talks could fail. A sale would simplify the company and raise cash, but the outcome is unclear, so the stock impact is uncertain.

    A major capital move that could reshape J&J and affect its price.

  • Competition in myeloma and ulcerative colitis AbbVie's etentamig showed positive Phase 3 results against J&J's Tecvayli, and rivals are advancing in ulcerative colitis. More competition could slow sales of J&J's drugs in these markets.

    A real counterweight to the positive pipeline news.

▲3

J&J wins new drug approvals, but valuation and self-cannibalization temper gains

  • FDA approves IMAAVY as first treatment for warm autoimmune hemolytic anemia The FDA approved J&J's IMAAVY as the first-ever treatment for warm autoimmune hemolytic anemia, a rare blood disease. This opens a brand-new market for a drug already approved for myasthenia gravis, adding future sales and reinforcing J&J's pipeline strength.

    This is a new regulatory approval that expands J&J's addressable market and supports future revenue growth.

  • China approves oral psoriasis drug Icotyde, opening a large market China approved J&J's once-daily oral psoriasis pill Icotyde, targeting over 8.4 million patients there. A pill is more convenient than injections, so it could become a blockbuster and take share from rivals, though it may also pull some patients away from J&J's own injectable Tremfya.

    This is a new geographic approval that opens a major market but carries a self-cannibalization risk.

  • FDA expands Stelara approval to pediatric ulcerative colitis The FDA expanded Stelara's use to children aged two and older with ulcerative colitis. This adds a new patient group for an existing drug, providing a modest sales boost and showing J&J continues to squeeze more value from its older medicines.

    This is a new label expansion that adds a pediatric indication, supporting incremental revenue.

  • New approvals face high valuation and commercial challenges J&J's stock trades about 40% above its GF Value estimate, so good news is already priced in. The new anemia drug faces adoption and reimbursement hurdles, and the China psoriasis pill could just shift sales from Tremfya. These factors limit how much the approvals can lift the stock near term.

    This is the key counterweight: high valuation and commercial execution risks mean the new approvals may not translate into immediate stock gains.

▲4

J&J lifts guidance, raises dividend, expands cancer and device pipeline

  • Guidance raised again on strong Q2 J&J lifted full-year sales guidance to about $101.1 billion and adjusted earnings to $11.68 a share, after quarterly sales of $25.3 billion beat expectations. Higher profit expectations make the stock more attractive and support its price.

    This is the period's core new financial event and directly lifts earnings expectations.

  • Dividend raised for 64th straight year J&J raised its quarterly dividend 3.1% to $1.34 a share, the 64th year in a row, backed by free cash flow that jumped to about $8.7 billion. A growing payout draws income investors and signals confidence in future cash.

    A new dividend increase is a fresh, concrete signal of financial strength that supports the stock.

  • Cancer and device pipeline keeps expanding New wins include European approval of TECVAYLI plus daratumumab for myeloma, FDA clearance for the AI-powered MONARCH QUEST 3 bronchoscopy system, and late-stage development of antidepressant Seltorexant. Each adds future sales and reinforces growth beyond Stelara.

    These are new approvals and pipeline advances that extend J&J's growth story.

  • Underlying growth is double-digit ex-Stelara Reported sales rose 5.6%, but excluding the shrinking Stelara generics drag, growth was double-digit. Tremfya jumped 71% to a first $2 billion quarter, and immunology and neuroscience are becoming new engines. This shows the core business is healthier than the headline.

    It explains why the Stelara patent cliff is no longer the dominant story and supports the bull case.

▲4

Analysts lift JNJ targets as talc deal and cancer sales build

  • Analyst price targets jump after strong Q2 A wave of firms (Scotiabank, Citi, Morgan Stanley, Goldman and others) raised JNJ price targets to roughly $260–$305, lifting the average fair value estimate to about $270.59 from $252.87. Higher targets pull money into the stock and support the share price.

    This is the period's clearest new price driver: broad analyst upgrades after earnings.

  • Talc settlement removes a long-running legal cloud J&J agreed to pay up to $5.5 billion to settle tens of thousands of talc lawsuits, provided at least 95% of claimants accept. Ending years of litigation makes J&J less risky to own and gives investors clearer visibility on future cash costs.

    The settlement is the biggest new event of the period and directly reduces legal risk weighing on the stock.

  • Cancer drug sales keep growing fast J&J's oncology revenue rose 16% to $7.4 billion, led by Darzalex (up about 18% to over $4 billion) and Erleada. Cancer is now nearly 29% of total sales, and J&J targets over $50 billion in annual cancer sales by 2030, supporting long-term growth.

    Oncology is J&J's main growth engine and the fresh sales figures show it is still accelerating.

  • OTTAVA surgical robot seen as a new growth market J&J's FDA-cleared OTTAVA robotic surgery system is being framed as a breakthrough that opens a new device market and could challenge Intuitive Surgical. Investors are watching adoption and orders, which could add a fresh revenue stream over time.

    The robot is a new product story that changes how investors value J&J's device business.

July 2026
▲3▼1

J&J Beats Q2, Raises Guidance, Settles Talc, But MedTech Lags

  • Q2 Beat, Raised Guidance, Dividend Increase J&J beat Q2 estimates for the ninth straight quarter, raised full-year revenue guidance to about $101 billion, and lifted its dividend for the 64th year. This shows steady profit growth and rewards shareholders.

    These are new financial results and capital returns that directly boost investor confidence.

  • Talc Settlement Removes Major Legal Overhang J&J settled about 76,000 talc claims for $5.5 billion, removing a large legal cloud. This reduces uncertainty that had weighed on the stock for years.

    The settlement is a new event that significantly lowers legal risk, a key prior concern.

  • Oncology Strength and Pipeline Expansion Darzalex, Tremfya, and Erleada offset Stelara's patent cliff. FDA clearance of the OTTAVA surgical robot, strong myeloma data, and new cancer deals expand future growth prospects.

    These new product advances and deals drive future revenue and offset patent losses.

  • MedTech Weakness and Firefly Bio EPS Dilution MedTech lagged with Abiomed heart-pump weakness and slowing electrophysiology growth. The Firefly Bio acquisition dilutes 2026 earnings by about $0.46 per share, and an Illinois court upheld a $45 million talc verdict, keeping some legal risk alive.

    These are new negative developments that partially offset the positive news and could pressure the stock.

▲3▼1

J&J settles talc for $5.5B, raises outlook, expands cancer pipeline

  • Talc settlement removes legal overhang J&J agreed to pay $5.5 billion to settle about 76,000 ovarian talc claims, with payments starting no earlier than 2027. This removes a huge legal cloud that had weighed on the stock for years, making J&J less risky to own and lifting shares over 2%.

    This is the single biggest new event of the period and directly reduces JNJ's legal risk, a key overhang.

  • Raised guidance and record Q2 sales J&J posted record quarterly sales of $25.3 billion, up 6.6%, and raised full-year revenue guidance to about $101.1 billion and EPS to $11.68. This puts J&J on track to top $100 billion in annual sales for the first time, boosting confidence in management.

    The raised outlook and record sales are new this period and directly support the stock's long-term value.

  • New cancer pipeline deals and FDA progress J&J partnered with Sail Biomedicines on in vivo CAR-T therapies, completed the $1 billion Firefly Bio acquisition, and won FDA Priority Review for RYBREVANT FASPRO in head and neck cancer. These expand the cancer pipeline and could drive future sales.

    These are new pipeline and regulatory wins that reinforce J&J's oncology growth story.

  • MedTech weakness and Firefly dilution MedTech sales missed estimates as Abiomed's heart pump sales fell 2% after a UK study, and J&J tempered its Abiomed outlook. The Firefly Bio deal will dilute 2026 EPS by about $0.46. These weigh on near-term results and raise doubts about the devices business.

    This is the main counterweight: a real weakness in MedTech and a dilution hit that could pressure the stock.

▲4

J&J's oncology pipeline and surgical robot drive growth

  • FDA clears OTTAVA robotic surgery system J&J won FDA authorization for its OTTAVA robotic surgical system, the first table-integrated soft-tissue robot. This opens a new medical-device growth market and could challenge Intuitive Surgical, adding a fresh revenue stream that supports the stock.

    New regulatory approval creates a new device growth engine, directly answering what is driving JNJ now.

  • TECVAYLI plus TALVEY cuts myeloma death risk 89% A Phase 3 trial showed the TECVAYLI-TALVEY combo cut the risk of progression or death by 89% in earlier-line multiple myeloma. Strong data like this supports wider use and future sales, reinforcing J&J's cancer leadership.

    New clinical data strengthens the oncology pipeline, a key growth driver for JNJ.

  • Oncology sales offset Stelara patent cliff Q2 Innovative Medicine sales rose 6.8% on strong Darzalex, Tremfya and Erleada demand, even as Stelara fell 55% on generics. J&J aims for $50 billion in annual cancer sales by 2030, showing the growth story is intact.

    Explains the core earnings engine and how new drugs are replacing lost revenue, central to JNJ's outlook.

  • Ninth straight earnings beat, guidance raised J&J beat Q2 estimates for the ninth quarter in a row and raised full-year sales and profit guidance, putting it on track to top $100 billion in revenue for the first time. Consistent beats build confidence in management and support the stock.

    Repeated earnings beats and raised guidance are a major reason investors are positive on JNJ right now.

▲3▼1

J&J beats Q2, raises guidance, but MedTech slowdown drags stock

  • Q2 earnings beat and raised 2026 guidance J&J reported Q2 sales of $25.31 billion, up 6.6%, and adjusted EPS of $2.90, both above estimates. It raised full-year revenue guidance to about $101.1 billion and EPS to $11.68. Strong drug sales, especially Tremfya and Darzalex, drove the beat, supporting the stock's long-term value.

    This is the period's biggest new event and directly shows J&J's financial health, a key price driver.

  • MedTech slowdown raises doubts about balanced growth Despite the overall beat, J&J's MedTech unit grew only 3.6% operationally, with cardiovascular sales falling 2% and electrophysiology growth slowing to 3.1%. The stock dropped 2.7% as investors worried that pharma strength is masking weakness in devices, threatening the two-engine growth story.

    This is the main counterweight this period and explains why the stock fell despite the earnings beat.

  • DePuy Synthes acquires Expanding Innovations for spine portfolio J&J's DePuy Synthes acquired Expanding Innovations, adding expandable implant technology for spine surgery. This strengthens its spine portfolio and competitive position in a growing market, supporting future MedTech sales and offsetting some weakness.

    A new acquisition that shows J&J is investing to strengthen its MedTech business, relevant to the growth narrative.

  • Amivantamab projected to lead US EGFR NSCLC revenue by 2036 A forecast shows J&J's amivantamab (with or without lazertinib) generating the highest US revenue in EGFR-mutated lung cancer by 2036, surpassing AstraZeneca's osimertinib. This reinforces J&J's oncology leadership and long-term sales potential.

    New analyst projection that highlights J&J's pipeline strength, a positive for future growth.

▲3▼1

J&J stays out of weight-loss race, boosts dividend, but talc appeal loss stings

  • J&J avoids GLP-1 race, focuses on oncology and devices CEO Joaquin Duato said J&J will not enter the GLP-1 weight-loss drug race, instead focusing on oncology and medical devices where it is strong. This avoids costly competition and supports steady growth, which can lift the stock.

    This is a new strategic decision that affects J&J's competitive position and future growth.

  • J&J raises dividend for 64th straight year and lifts outlook J&J increased its dividend 3.1% to $1.34 per share, marking 64 consecutive years of hikes, and raised full-year revenue guidance to $100.3–$101.3 billion. This signals confidence and appeals to income investors, supporting the stock price.

    This is a new event that directly boosts investor confidence and income appeal.

  • Planned orthopedics spinoff seen as catalyst to boost valuation J&J plans to spin off its DePuy Synthes orthopedics business within 18–24 months. Jim Cramer highlighted this as a catalyst to raise J&J's price-to-earnings multiple, similar to the Kenvue separation. This can unlock value and attract more investors.

    This is a new development that could re-rate the stock and is being actively discussed by influential investors.

  • Illinois court upholds $45 million talc verdict against J&J An Illinois appellate court affirmed a $45 million mesothelioma verdict against J&J and Kenvue, rejecting J&J's appeals. This increases legal risk and potential liabilities from talc lawsuits, which can weigh on the stock price.

    This is a new legal setback that adds to J&J's talc litigation overhang and could pressure the stock.

Q2 2026
▲3▼1

J&J's June: Pipeline Wins, $55B Investment, But CARVYKTI Slows

  • TALVEY Phase 3 Win and European Approval for Tecvayli J&J's TALVEY succeeded in a late-stage multiple myeloma trial, and Tecvayli won European approval. These advances strengthen J&J's cancer drug lineup and support future revenue growth.

    New clinical and regulatory wins are key positive drivers for J&J's growth outlook.

  • $55B U.S. Investment Plan and Firefly Bio Acquisition J&J announced a $55 billion U.S. investment plan aimed at double-digit growth and acquired Firefly Bio for $1 billion. These moves signal confidence and expand its innovative medicine pipeline.

    Major capital commitments and a strategic acquisition are new positive developments for J&J.

  • Talc Lawsuit Victory and Raised 2026 Guidance J&J won a talc lawsuit, reducing legal risk, and raised its 2026 guidance with a $100 billion revenue target. This boosts investor confidence in the company's financial trajectory.

    Legal relief and improved guidance are new positive catalysts for J&J's stock.

  • CARVYKTI Growth Deceleration and Pending Talc Lawsuits CARVYKTI's growth slowed to 57.4% from 63.2%, raising concerns about J&J's premium valuation. Over 67,000 talc lawsuits remain pending, and the stock's modest 6.4% gain suggests investors seek more proof of accelerating growth.

    These are new negative factors that temper the positive outlook and explain the stock's muted reaction.

June 2026
▲3▼1

J&J's June: Pipeline Wins, $55B Investment, But CARVYKTI Slows

  • TALVEY Phase 3 Win and European Approval for Tecvayli J&J's TALVEY succeeded in a late-stage multiple myeloma trial, and Tecvayli won European approval. These advances strengthen J&J's cancer drug lineup and support future revenue growth.

    New clinical and regulatory wins are key positive drivers for J&J's growth outlook.

  • $55B U.S. Investment Plan and Firefly Bio Acquisition J&J announced a $55 billion U.S. investment plan aimed at double-digit growth and acquired Firefly Bio for $1 billion. These moves signal confidence and expand its innovative medicine pipeline.

    Major capital commitments and a strategic acquisition are new positive developments for J&J.

  • Talc Lawsuit Victory and Raised 2026 Guidance J&J won a talc lawsuit, reducing legal risk, and raised its 2026 guidance with a $100 billion revenue target. This boosts investor confidence in the company's financial trajectory.

    Legal relief and improved guidance are new positive catalysts for J&J's stock.

  • CARVYKTI Growth Deceleration and Pending Talc Lawsuits CARVYKTI's growth slowed to 57.4% from 63.2%, raising concerns about J&J's premium valuation. Over 67,000 talc lawsuits remain pending, and the stock's modest 6.4% gain suggests investors seek more proof of accelerating growth.

    These are new negative factors that temper the positive outlook and explain the stock's muted reaction.

▲4

J&J hits record on cancer wins, $1B deal, raised outlook

  • Talc cancer lawsuit win cuts legal risk A Los Angeles jury found J&J not negligent in a talc-cancer case. With over 67,000 similar lawsuits pending, any win lowers the chance of huge payouts and makes the stock less risky to own.

    This is a new legal victory that directly reduces a major overhang on JNJ shares.

  • Firefly Bio acquisition expands cancer pipeline J&J agreed to buy Firefly Bio for $1 billion in cash, gaining a new way to attack cancer cells. This adds to its pipeline and supports its goal of becoming the top cancer company by 2030, which can drive future sales.

    This is a new acquisition that strengthens JNJ's oncology growth story.

  • European approval for Tecvayli combo boosts sales Europe's drug regulator recommended expanding Tecvayli's use in multiple myeloma, based on strong trial results. This makes the drug available to more patients earlier, likely increasing sales and reinforcing J&J's leadership in blood cancer.

    This is a new regulatory win that expands a key drug's market.

  • Raised 2026 outlook and $100B revenue target J&J raised its 2026 revenue growth guidance to 6.1% and says it's on track to hit $100 billion in annual revenue for the first time. This signals confidence in accelerating growth, though the stock has only gained 6.4% since, suggesting investors want more proof.

    This is a new financial outlook that directly addresses JNJ's growth trajectory.

▲3▼1

J&J's oncology pipeline and $55B U.S. investment drive growth outlook

  • TALVEY Phase 3 win in multiple myeloma Positive Phase 3 results for TALVEY plus DARZALEX FASPRO showed superior progression-free survival in multiple myeloma, with up to 72% reduced risk of progression or death. This supports label expansion and could shift treatment guidelines, boosting J&J's oncology franchise and future sales.

    New clinical win directly strengthens J&J's cancer business, a key growth driver.

  • CEO commits $55B U.S. investment, targets double-digit growth CEO Joaquin Duato sees a path to double-digit growth and plans $55 billion in U.S. investment over four years, starting with a new biologics plant. This signals confidence in long-term growth and expands domestic manufacturing, which can lower supply risks and support earnings.

    New capital commitment and growth target show management's strategic direction and confidence.

  • New product launches and data expand treatment options J&J launched a dual-energy catheter ablation platform in Europe and presented new IMAAVY data reinforcing sustained disease control in myasthenia gravis. These advances broaden the medical device and pharma portfolios, supporting future revenue growth.

    New product launches and clinical data are fresh positive developments for J&J's business.

  • CARVYKTI growth deceleration raises valuation concerns CARVYKTI's year-over-year growth slowed to 57.4% from 63.2%, raising questions about its ramp-up. With J&J's stock trading near a 10-year high price-to-sales multiple, any further cooling could pressure the premium valuation and challenge the growth narrative.

    This is a real counterweight: a key growth drug showing slower momentum could weigh on the stock.

© 2026 MarketIVWhy